The Streptococcal Pneumonia drugs in development market research report provides comprehensive information on the therapeutics under development for Streptococcal Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Streptococcal Pneumonia. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Streptococcal Pneumonia and features dormant and discontinued products.

GlobalData tracks 89 drugs in development for Streptococcal Pneumonia by 62 companies/universities/institutes. The top development phase for Streptococcal Pneumonia is preclinical with 34 drugs in that stage. The Streptococcal Pneumonia pipeline has 79 drugs in development by companies and ten by universities/ institutes. Some of the companies in the Streptococcal Pneumonia pipeline products market are: Pfizer, Panacea Biotec and Aeolian Biotech.

The key targets in the Streptococcal Pneumonia pipeline products market include Poly N-Acetyl Glucosamine (PNAG), Streptococcus pneumoniae Pneumococcal Surface Protein A (pspA), and DNA Polymerase III (EC 2.7.7.7).

The key mechanisms of action in the Streptococcal Pneumonia pipeline product include DNA Polymerase III (EC 2.7.7.7) Inhibitor with two drugs in Preclinical. The Streptococcal Pneumonia pipeline products include eight routes of administration with the top ROA being Intramuscular and 11 key molecule types in the Streptococcal Pneumonia pipeline products market including Conjugate Vaccine, and Small Molecule.

Streptococcal Pneumonia overview

Streptococcus pneumoniae, or pneumococcus, is a Gram-positive spherical bacteria, and alpha-hemolytic member of the genus Streptococcus. Pneumococcal infections are present throughout the world and are most common during the winter and early spring months. Pneumoniae is prevalent in large part due to its colonizing ability in the nasopharynx. Almost 40-50% healthy children and 20-30% of healthy adults are carriers. With childhood conjugate vaccination for Streptococcus pneumoniae, the colonization frequency has decreased. Infection typically occurs after the colonization of the oropharynx and nasopharynx of healthy individuals. Inhalation of these colonies causes the infection of the lower airways. Infection typically will not result unless a patient has predisposed risk factors, a bolus of infectious cells, or colonization with a particularly virulent strain of S. pneumoniae. The Streptococcus pneumoniae cell capsule plays a major role in its pathogenesis; it is made up of polysaccharides and surrounds the cell wall. It helps in escaping phagocytosis by preventing the access of granulocytes to the underlying cell wall.

For a complete picture of Streptococcal Pneumonia’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.